This finding is consistent with the lack of increased mammary epithelial Ki-67 labeling reported previously [21] and the lack of increased breast cancer risk among older postmenopausal women receiving tibolone in the LIFT clinical trial [12]. Here, MKI67 is linked to breast carcinoma.